Simultaneous determination of L-702,007, a HIV-1 reverse transcriptase inhibitor, and its 6-hydroxy metabolite in human plasma by column-switching high-performance liquid chromatography with fluorescence detection.
A method for the determination of L-702,007, a human immunodeficiency virus type 1 reverse transcriptase inhibitor, and its 6-hydroxy metabolite in human plasma is described. Plasma samples are extracted using phenyl solid-phase extraction columns. The extract is analyzed by HPLC using a column-switching system to remove interferences from late-eluting endogenous components. Fluorescence detection at an excitation wavelength of 314 nm and an emission wavelength of 390 nm is utilized. The assay was validated in the concentration range of 10-200 ng/ml when 1-ml aliquots of plasma were extracted. The assay has been used to support human pharmacokinetic studies.
Woolf
E J
EJ
Merck Research Laboratories, Department of Drug Metabolism, West Point, PA 19486, USA.
Matuszewski
B
B
D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D054303:HIV Reverse Transcriptase / Q000378:metabolism*; D015497:HIV-1 / Q000201:enzymology*; D006801:Humans; D006900:Hydroxylation; D011728:Pyridones / Q000097:blood* / Q000493:pharmacokinetics; D011786:Quality Control; D012015:Reference Standards; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D013050:Spectrometry, Fluorescence
D011728:Pyridones; D018894:Reverse Transcriptase Inhibitors; C079292:L 702007; D054303:HIV Reverse Transcriptase